pAb-056-050 (Diagenode lot A93-0042), showed high affinity to H3K9me3 and almost no cross-reactivity to the other peptides, indicating excellent quality. Unfortunately, this lot is no longer available, and another lot of the same product exhibited lower quality (Fig. 1a) . Histone PTMs are challenging targets for antibody recognition because the chemical differences among PTMs are minute, in particular among methylation states, and because there is a high level of sequence similarity surrounding the different modification sites. Furthermore, it is difficult to achieve high affinity to a flexible peptide, such as histone tails, because of a large entropic loss associated with binding 8 . Consequently, the difficulty in generating high-quality antibodies, regardless of antibody-generation methods, is not unexpected.
We first identified, from a human naive antibody library 9 , a single chain Fv (scFv) clone, termed 'scFv4-5' , that bound to trimethylated lysine with high specificity but low affinity and low sequence specificity (Supplementary Fig. 2a-c) . To improve the binding function, we identified positions that are important for recognition of trimethylated lysine using shotgun-scanning mutagenesis 10 (Supplementary Fig. 2d,e ). We then used the mutagenesis data to design a tailored phage-display library and sorted it for specific H3K9me3 binding. We converted candidate clones into the Fab format ( Supplementary Fig. 2b) , expressed them in Escherichia coli, purified them and characterized them using the peptide immunoprecipitation assay. One clone, termed 309M3-A, had a K D of 24 nM to H3K9me3, representing ~80-fold improvement from scFv4-5, and almost no binding to the other peptides tested, indicating both high affinity and high specificity ( Fig. 1b and Supplementary Fig. 3a,b) . Two independent preparations of the 309M3-A antibody showed no substantial lot-to-lot variation ( Supplementary Fig. 3a ). Its binding capacity, defined as the amount of peptide that an equivalent amount of an antibody captures, was higher than that of most polyclonal anti-H3K9me3 antibodies including pAb-056-050 (Diagenode lot A93-0042), the best commercial antibody we found ( Supplementary Fig. 3c ). We also designed a nonfunctional antibody, termed 'NegM3' , by mutating four residues of scFv4-5. This should be a more appropriate control for identifying background effects from the antibody framework than generic 'IgG controls' of unknown properties that are often used in ChIP experiments. As we demonstrated here, the iterative process of designing a library and characterizing antibodies can produce highly functional antibodies. Such improvement is nearly impossible for conventional polyclonal and monoclonal antibodies, illustrating a clear advantage of recombinant antibodies.
recombinant antibodies to histone post-translational modifications
Variability in the quality of antibodies to histone posttranslational modifications (Ptms) is a widely recognized hindrance in epigenetics research. here, we produced recombinant antibodies to the trimethylated lysine residues of histone h3 with high specificity and affinity and no lot-tolot variation. these recombinant antibodies performed well in common epigenetics applications, and enabled us to identify positive and negative correlations among histone Ptms.
PTMs of histone proteins have key roles in epigenetic regulation 1, 2 . Antibodies to histone PTMs are critical components in investigations of epigenetics, such as chromatin immunoprecipitation (ChIP), immunostaining and immunoblotting 3, 4 , but many antibodies to histone PTMs do not specifically recognize their intended targets [5] [6] [7] . Furthermore, currently available anti-histone antibodies are mostly polyclonal, and hence each lot of antibody is a different product that needs to be extensively validated before use.
Here we describe high-quality recombinant antibodies to histone PTMs, generated to address this 'antibody bottleneck' . We concentrated our initial efforts in obtaining high-quality anti-H3K9me3 antibodies. We had recently established a quantitative peptide immunoprecipitation assay to determine the dissociation constant (K D ), the fundamental parameter defining affinity and specificity, and characterized a panel of commercial antibodies 7 . We had identified an excellent anti-H3K4me3 antibody, but all anti-H3K9me3 antibodies (two polyclonal and one monoclonal) tested were of poor quality 7 . Thus, we expanded our survey of anti-H3K9me3 antibodies. The affinity, specificity and binding capacity of commercial anti-H3K9me3 antibodies varied greatly ( Fig. 1a and Supplementary Fig. 1 ). Of eight antibodies, including those reported previously 7 , only a polyclonal antibody, Although antibodies to histone PTMs are often influenced by combinatorial PTMs adjacent to their targeted mark 11 , our 309M3-A antibody was generally insensitive to neighboring modifications. Modifications on the H3K9me3 peptide at K4, T6, R8 or S10 resulted in only small changes in affinity of 309M3-A ( Fig. 1c) . In contrast, a single secondary modification reduced the affinity of pAb-056-050 (Diagenode lot A93-0042) by >50-fold ( Fig. 1c ), suggesting that this antibody achieves its high functionality by recognizing features over several residues surrounding H3K9me3. Thus, 309M3-A is a suitable reagent for capturing histones containing the H3K9me3 mark without a strong bias in terms of adjacent modifications.
The 309M3-A antibody specifically recognized full-length histone H3 from human cell lines ( Supplementary Fig. 3d ). Immunostaining of NIH 3T3 cells with it yielded a punctate pattern where the foci overlapped with those of the fluorochrome 4′,6′-diamidino-2-phenylindole (DAPI) staining ( Fig. 1d) . This pattern indicated that 309M3-A staining was concentrated in the pericentric heterochromatin regions, regions enriched with H3K9me3 (ref. 12 ), suggesting that 309M3-A recognizes the H3K9me3 in the nucleus.
In addition to anti-H3K9me3 antibodies, we developed anti-H3K4me3 antibodies. One clone, named 304M3-A, exhibited a K D value of 16 nM to H3K4me3 with high specificity and no substantial lot-to-lot variation ( Supplementary Fig. 4a,b) . The affinity of 304M3-A was negatively affected by PTMs of R2, T3, T6 and the N-terminal backbone amine ( Supplementary  Fig. 4c ), indicating that this antibody, unlike 309M3-A, achieved specificity by recognizing features spanning from the N terminus to residue 6. Together, these results strongly suggest the feasibility of generating high-quality recombinant antibodies to a range of histone PTMs.
As ChIP is arguably the most important application of antibodies to histone PTMs, we tested our recombinant antibodies in ChIP experiments. ChIP from HEK293 cells with 309M3-A and 304M3-A, respectively, enriched specific loci marked with H3K9me3 (3′ ends of zinc finger genes) and H3K4me3 (human HOXA9 and GAPDH) 13, 14 (Fig. 2a) . In contrast, the negative control antibody, whose Fv portion differs from that of the lead antibody, scFv4-5, by only four residues, enriched none of these loci, indicating low background binding of the antibody framework. Although ChIP from HEK293T cells with 309M3-A and pAb-056-050 (lot A93-0042) resulted in similar profiles in ChIP followed by quantitative PCR (ChIP-qPCR) and ChIP followed by high-throughput sequencing (ChIP-seq), 309M3-A yielded higher enrichment ( Supplementary Fig. 5a,b) . This difference in enrichment is consistent with the difference in binding capacity of the two antibodies revealed in the peptide immunoprecipitation assay (Supplementary Fig. 3c ). Finally, ChIP-seq data of Drosophila melanogaster embryos revealed highly correlated peak patterns between biological replicates, indicating high reproducibility ( Fig. 2b) . Together, these data demonstrated that the recombinant antibodies performed well in ChIP experiments with a variety of chromatin samples.
To further examine the specificity and utility of 309M3-A antibody, we performed immunoprecipitation followed by mass spectrometry (IP-MS), which directly quantifies histone modifications 15 (Supplementary Fig. 6a ). Immunoprecipitation with 309M3-A of GluC-digested fragments of histone H3 highly enriched fragments containing H3K9me3 (from 23% to 79%) and depleted those containing H3K9me2, the most abundant mark identified for H3K9 (from 45% to 8%; Fig. 2c ), confirming that 309M3-A selectively enriched histone fragments containing H3K9me3. Although the additional R8 modifications on the H3K9me3 peptide slightly increased the affinity of 309M3-A to H3K9me3 (Fig. 1c) , we did not observe enrichment of a peptide containing H3K9me3 and R8 modification, suggesting that the immunoprecipitation efficiency was not strongly biased by secondary modifications. IP-MS analysis also enabled us to determine combinations of multiple histone PTMs residing in the same histone tail. We found that 25% of captured peptides containing H3K9me3 also had H3K14Ac (Supplementary Fig. 6b ), npg brief communications indicating these two marks often coexist. Trimethylation at K27 increased threefold after immunoprecipitation ( Fig. 2c and Supplementary Fig. 6c,d) . Because 309M3-A exhibited no detectable binding to the H3K27me3 peptide ( Fig. 1b) , these data suggest that H3K9me3 partially coexisted with H3K27me3. In contrast, H3K36me2 was dramatically decreased after immunoprecipitation, indicating negative correlation between H3K9me3 and H3K36me2 ( Fig. 2c and Supplementary Fig. 6c,d) . This negative correlation could be deduced from the positive correlation between H3K9me3 and H3K27me3 as described above and negative correlation between H3K27me2 or H3K27me3 and H3K36me2 or H3K36me3 reported recently 16 . Together, the high specificity of the recombinant antibody enabled us to identify both positive and negative correlations among histone PTMs. Finally, we exploited the high specificity and renewability of 309M3-A to develop an assay for histone methyltransferase (HMT) activity. HMT and histone demethylase are emerging drug targets 17 , but low specificity of antibodies is a serious impediment to developing antibody-based screening assays for these enzymes 18 . We first evaluated our recombinant antibody and commercial antibodies for their ability to discriminate H3K9me2 and H3K9me3. The antibody 309M3-A exhibited a large dynamic range and identical profiles between two lots, superior to that of a polyclonal antibody, Ab8898 (Fig. 2d) . This assay with 309M3-A clearly detected the activity of the methyltransferase SUV39H1 and its inhibition by chaetocin 17 (Fig. 2e) . These results illustrate that the high specificity and consistent quality of recombinant antibodies are ideally suited for developing HMT assays.
The truly renewable nature of recombinant antibodies justifies efforts and expenses for comprehensive validation, which liberates individual investigators from the need to evaluate each antibody. Recombinant antibodies can be engineered into different formats suitable for particular applications. An intriguing possibility is the development of 'intrabodies' , which are intracellularly expressed antibodies, for real-time detection and perturbation of intracellular events 19 . Thus, recombinant antibodies to histone PTMs can not only dramatically accelerate and improve the quality of epigenetics research but also enable new investigations.
methods
Methods and any associated references are available in the online version of the paper. npg online methods Peptides and commercial antibodies. Peptide sequences are given in Supplementary Figure 1a . Synthetic peptides were purchased from Abgent and Genemed Synthesis, or synthesized in-house 11 . Peptides were biotinylated as described previously 7 . Antibodies were purchased from their respective vendors.
Peptide immunoprecipitation assay. For commercial antibodies, 100 µl of protein A or protein G-coated polystyrene beads (Spherotech Inc.) and 1 µg of an antibody sample were incubated for 1 h at 4 °C to prepare antibody-coated beads. For recombinant antibodies, which were produced in the form of biotinylated Fab, 100 µl of streptavidin-coated polystyrene beads (Spherotech Inc.) and 0.6 µg of a biotinylated Fab sample (equivalent to 1 µg of IgG antibody) were incubated and then excess biotin-binding sites of streptavidin were blocked with biotin. These antibody-coated beads were used for the assay as described previously 7 .
Although it is technically true that the assay measures the combined strength of all interactions involved (sometimes called 'avidity'), in practice the assay essentially measures the affinity of the interaction between an antibody and a peptide. The K D values for the interaction of protein A with rabbit IgG (or protein G with mouse IgG) are in the single-nanomolar or sub-nanomolar range 20 , much lower than the 'net K D ' values that we found for the antibody-peptide interactions in the assay. Therefore, these results indicate that the contribution of the interaction between protein A or protein G and IgG to the determined K D value is negligible and that our assay effectively analyzes the interaction between antibody and peptide. Likewise, the interaction between biotin and streptavidin is extremely tight, and thus the assay for biotinylated Fab measures the affinity of the antibodypeptide interaction.
In vitro selection of recombinant antibodies. Selection of recombinant antibodies from a human naive library using yeast display was performed as described 21 , except that the first round of selection was performed using antigen-coated magnetic beads as previously described 22 . Biotinylated peptides were used as antigen ( Supplementary Fig. 1a ). In the first round, streptavidin magnetic beads were first incubated with excess amounts of a biotinylated peptide and used for selection. In the second round, a biotinylated peptide at 2 µM was used for library sorting using FACS.
A phage display vector of scFv4-5 was constructed by cloning the DNA encoding the scFv segment in the DsbFNp3FL vector 23 . This vector displays the scFv on the surface of M13 bacteriophage as a fusion protein to the C-terminal domain of the M13 p3 coat protein. Shotgun-scanning mutagenesis analysis was performed following the method in ref. 10 . Residues in the complementarity determining regions (CDRs) were diversified with a binary choice of the amino acid that occurs in the wild type and either serine or alanine. When such a binary code could not be encoded using a 'wobble' codon, a codon encoding four amino acids was used. Specifically, codons and encoded amino acids used here were: KCT (where K is G or T) for Ala or Ser; GMT (where M is A or C) for Asp or Ala; TYT (where Y is C or T) for Phe or Ser; GST (where S is C or G) for Gly or Ala; MRT (where R is A or G) for His, Ser, Arg or Asn; AKT for Ile or Ser; RMA for Lys, Ala, Thr or Glu; TYG for Leu or Ser; RYG for Met, Ala, Thr or Val;
ART for Asn or Ser; MCT for Pro or Ala; SMA for Gln, Ala, Pro or Glu; AGW (W = A or T) for Arg or Ser; RCT for Thr or Ala; GYT for Val or Ala; TSG for Trp or Ser; TMT for Tyr or Ser. The ratio of the amino acid that occurs in the wild type over a replacement at each mutated position was determined for recovered clones that retained binding to H3K4me3 or H3K9me3 by DNA sequencing.
A phage-display library was constructed based on analysis of shotgun-scanning mutagenesis, in which residues in the CDRs of scFv4-5 were randomized. This library was subjected to selection for binding to H3K9me3 or H3K4me3 peptides that also include negative selection against other peptides, essentially following published methods 24 . A biotinylated peptide at 100 nM was used for selections. Clones that had high specificity were identified by phage ELISA analysis.
Expression and purification of recombinant antibodies. scFv clones were reformatted into the Fab form using an expression vector previously described 25 . Here the C H1 and C L portions of the 4D5 antibody were attached to the V H and V L portions, respectively, derived from scFv clones. The antibodies additionally contained a biotinylation acceptor peptide at the C terminus of the heavy chain. The antibodies were expressed in E. coli 55244 (ATCC) harboring a plasmid that coexpressed the BirA biotin ligase in medium supplemented with biotin. Fab samples were loaded on a HiTrap Protein G HP column (GE Healthcare) using 20 mM sodium phosphate buffer and eluted with 0.1 M Gly-HCl (pH 2.7). The eluted Fab samples were further purified on a Resource S column (GE Healthcare) using a linear gradient of NaCl in 50 mM sodium acetate buffer (pH5.0). Purity was verified by SDS-PAGE.
Western blot analysis. The K562 cells were grown in the RPMI 1640 medium (Gibco) with 2 mM l-glutamine, 10% FBS and antibiotics. Whole-cell extracts of K562 cells (1 × 10 6 ) were separated using SDS-PAGE and blotted to a nitrocellulose membrane. The membrane was blocked with PBST buffer (PBS and 0.05% Tween 20) containing 5% skim milk and rinsed with PBST buffer. The membrane was probed with 309M3-A or commercial antibodies in PBST containing 1% BSA using a multichannel western blotting apparatus (Idea Scientific Company). The 309M3-A antibody was detected with horseradish peroxidase (HRP)-conjugated neutravidin (Pierce) and polyclonal antibodies were detected with goat anti-rabbit IgG-HRP (Pierce).
Immunofluorescence analysis. NIH 3T3 cells were grown in the DMEM (Cellgro) with 2 mM l-glutamine, 10% FBS and antibiotics. Immunofluorescence analysis was performed as described 26 . The rabbit polyclonal antibody was detected with Dylight650 conjugated anti-rabbit polyclonal antibody (Pierce). Recombinant antibodies were first mixed with Dylight650-conjugated streptavidin (Pierce) at a molar ratio of 4:1 to form antibody-streptavidin complexes. After 30 min incubation at 4 °C, excess biotin-binding sites of streptavidin were blocked with biotin, and then the antibody-streptavidin complexes were used in staining of the cells. Native chromatin immunoprecipitation followed by quantitative PCR. Native ChIP experiments using HEK293 cells were performed as previously described 27 with the following npg
